Browse Arkansas Code titles and sections
42 U.S.C. § 283 — Triennial reports of Director of NIH
Federal law — U.S. Code and appendices · legal_authorities
**(a) In general** The Director of NIH shall submit to the Congress on a triennial basis a report in accordance with this section. The first report shall be submitted not later than 1 year after January 15, 2007. Each such report shall include the following information:
(1) An assessment of the state of biomedical and behavioral research.
(2) A description of the activities conducted or supported by the agencies of the National Institutes of Health and policies respecting the programs of such agencies.
(3) A description of intra-National Institutes of Health activities, including—
(A) identification of the percentage of funds made available by each national research institute and national center with respect to each applicable fiscal year for conducting or supporting research that involves collaboration between the institute or center and 1 or more other national research institutes or national centers; and
(B) recommendations for promoting coordination of information among the centers of excellence.
(4) A catalog of all the research activities of the agencies, prepared in accordance with the following:
(A) The catalog shall, for each such activity—
(i) identify the agency or agencies involved;
(ii) state whether the activity was carried out directly by the agencies or was supported by the agencies and describe to what extent the agency was involved; and
(iii) identify whether the activity was carried out through a center of excellence.
(B) In the case of clinical research, the catalog shall, as appropriate, identify study populations by demographic variables, including biological and social variables and relevant age categories (such as pediatric subgroups), and determinants of health, that contribute to research on minority health and he
Source: Supplied U.S. Code snapshot — release unconfirmed · 42 U.S.C. § 283
Stored review status: release_metadata_unconfirmed. A text match is a research starting point; applicability is not established.
Original supplied file — preserved unchanged
Download original Markdown file
File SHA-256: 57b8f33a7f2295e3f6869d2aff4c3ac1a94cff63ae83b53494cfecef2e2e0c52. The original may include catalog metadata, neighboring provisions, or embedded records outside this collection's scope. Search shows only the selected federal record. Historical editions and unverified snapshots are not a statement of current law.
Authority boundary: historical or unconfirmed source not current law verified.
Open the recorded source website ↗
Record provenance
Stable record: federal_law:legal_authorities:record_usc_77732ed7917cca36f25189b9
Source file: Laws/federal/codes/united-states-code/title-42/section-283-triennial-reports-of-director-of-nih--88cb7b012e.md
Pages: Not recorded – Not recorded
Passage SHA-256: 205184ae8fcedbd4e8d90c4ed8d4545420c588d5309e05d4a6d0416fec3488be
Source location: Title 42, Chapter 6A, § 283; chapter-6a-public-health-service.md
Stored source content
**(a) In general** The Director of NIH shall submit to the Congress on a triennial basis a report in accordance with this section. The first report shall be submitted not later than 1 year after January 15, 2007. Each such report shall include the following information:
(1) An assessment of the state of biomedical and behavioral research.
(2) A description of the activities conducted or supported by the agencies of the National Institutes of Health and policies respecting the programs of such agencies.
(3) A description of intra-National Institutes of Health activities, including—
(A) identification of the percentage of funds made available by each national research institute and national center with respect to each applicable fiscal year for conducting or supporting research that involves collaboration between the institute or center and 1 or more other national research institutes or national centers; and
(B) recommendations for promoting coordination of information among the centers of excellence.
(4) A catalog of all the research activities of the agencies, prepared in accordance with the following:
(A) The catalog shall, for each such activity—
(i) identify the agency or agencies involved;
(ii) state whether the activity was carried out directly by the agencies or was supported by the agencies and describe to what extent the agency was involved; and
(iii) identify whether the activity was carried out through a center of excellence.
(B) In the case of clinical research, the catalog shall, as appropriate, identify study populations by demographic variables, including biological and social variables and relevant age categories (such as pediatric subgroups), and determinants of health, that contribute to research on minority health and health disparities.
(C) Research activities listed in the catalog shall include, where applicable, the following:
(i) Epidemiological studies and longitudinal studies.
(ii) Disease registries, information clearinghouses, and other data systems.
(iii) Public education and information campaigns.
(iv) Training activities, including—
(I) National Research Service Awards and Clinical Transformation Science Awards;
(II) graduate medical education programs, including information on the number and type of graduate degrees awarded during the period in which the programs received funding under this subchapter;
(III) investigator-initiated awards for postdoctoral training and postdoctoral training funded through research grants;
(IV) a breakdown by demographic variables and other appropriate categories; and
(V) an evaluation and comparison of outcomes and effectiveness of various training programs.
(v) Clinical trials, including a breakdown of participation by study populations and demographic variables, including relevant age categories (such as pediatric subgroups), information submitted by each national research institute and national center to the Director of National Institutes of Health under [section 289a–2(f) of this title](https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title42-section289a–2/f&num=0&edition=prelim), and such other information as may be necessary to demonstrate compliance with [section 289a–2 of this title](https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title42-section289a-2&num=0&edition=prelim) and other applicable requirements regarding inclusion of demographic groups.
(vi) Translational research activities with other agencies of the Public Health Service.
(5) A summary of the research activities throughout the agencies, which summary shall be organized by the following categories, where applicable:
(A) Cancer.
(B) Neurosciences.
(C) Life stages, human development, and rehabilitation.
(D) Organ systems.
(E) Autoimmune diseases.
(F) Genomics.
(G) Molecular biology and basic science.
(H) Technology development.
(I) Chronic diseases, including pain and palliative care.
(J) Infectious diseases and bioterrorism.
(K) Minority health and health disparities.
(L) Such additional categories as the Director determines to be appropriate.
(6) A review of each entity receiving funding under this subchapter in its capacity as a center of excellence (in this paragraph referred to as a “center of excellence”), including the following—
(A) an evaluation of the performance and research outcomes of each center of excellence; and
(B) recommendations for improving the effectiveness, efficiency, and outcomes of the centers of excellence.
**(b) Requirement regarding disease-specific research activities** In a report under subsection (a), the Director of NIH, when reporting on research activities relating to a specific disease, disorder, or other adverse health condition, shall—
(1) present information in a standardized format;
(2) identify the actual dollar amounts obligated for such activities; and
(3) include a plan for research on the specific disease, disorder, or other adverse health condition, including a statement of objectives regarding the research, the means for achieving the objectives, a date by which the objectives are expected to be achieved, and justifications for revisions to the plan.
**(c) Additional reports** In addition to reports required by subsections (a) and (b), the Director of NIH or the head of a national research institute or national center may submit to the Congress such additional reports as the Director or the head of such institute or center determines to be appropriate.
Cross-references
Connections may be documented source relationships, shared citations or nearby passages. Each explains its basis; a connection alone does not establish applicability to your situation.
Federal law — U.S. Code and appendices · legal_authorities
**(a) Relation to Public Health Service** The National Institutes of Health is an agency of the Service.
**(b) National research institutes and national centers** The following agencies of the National Institutes of Health are national research institutes or national centers:
(1) The National Cancer Institute.
(2) The National Heart, Lung, and Blood Institute.
(3) The National Institute of Diabetes and Digestive and Kidney Diseases.
(4) The National Institute of Arthritis and Musculoskeletal and Skin Diseases.
(5) The National Institute on Aging.
(6) The National Institute of Allergy and Infectious Diseases.
(7) The Eunice Kennedy Shriver National Institute of Child Health and Human Development.
(8) The National Institute of Dental and Craniofacial Research.
(9) The National Eye Institute.
(10) The National Institute of Neurological Disorders and Stroke.
(11) The National Institute on Deafness and Other Communication Disorders.
(12) The National Institute on Alcohol Abuse and Alcoholism.
(13) The National Institute on Drug Abuse.
(14) The National Institute of Mental Health.
(15) The National Institute of General Medical Sciences.
(16) The National Institute of Environmental Health Sciences.
(17) The National Institute of Nursing Research.
(18) The National Institute of Biomedical Imaging and Bioengineering.
(19) The National Human Genome Research Institute.
(20) The National Library of Medicine.
(21) The National Center for Advancing Translational Sciences.
(22) The John E. Fogarty International Center for Advanced Study in the Health Sciences.
(23) The National Center for Complementary and Integrative Health.
(24) The National Institute on Minority Health and Health Disparities.
(25) Any other national center that, as an agency separate from
Source: Supplied U.S. Code snapshot — release unconfirmed · 42 U.S.C. § 281
Stored review status: release_metadata_unconfirmed. Explicit cross-reference supplied in source Markdown; currentness and applicability require review.
Federal law — U.S. Code and appendices · legal_authorities
**(a)**
(1) When requested by a committee of Congress having jurisdiction over receipts or appropriations, the President shall provide the committee with assistance and information.
(2) When requested by a committee of Congress, additional information related to the amount of an appropriation originally requested by an Office of Inspector General shall be submitted to the committee.
**(b)** When requested by a committee of Congress, by the Comptroller General, or by the Director of the Congressional Budget Office, the Secretary of the Treasury, the Director of the Office of Management and Budget, and the head of each executive agency shall—
(1) provide information on the location and kind of available fiscal, budget, and program information;
(2) to the extent practicable, prepare summary tables of that fiscal, budget, and program information and related information the committee, the Comptroller General, or the Director of the Congressional Budget Office considers necessary; and
(3) provide a program evaluation carried out or commissioned by an executive agency.
**(c)** In cooperation with the Director of the Congressional Budget Office, the Secretary, and the Director of the Office of Management and Budget, the Comptroller General shall—
(1) establish and maintain a current directory of sources of, and information systems for, fiscal, budget, and program information and a brief description of the contents of each source and system;
(2) when requested, provide assistance to committees of Congress and members of Congress in obtaining information from the sources in the directory; and
(3) when requested, provide assistance to committees and, to the extent practicable, to members of Congress in evaluating the information obtained from the sources in the directory
Source: Supplied U.S. Code snapshot — release unconfirmed · 31 U.S.C. § 1113
Stored review status: release_metadata_unconfirmed. Incoming connection: Explicit cross-reference supplied in source Markdown; currentness and applicability require review.
Federal law — U.S. Code and appendices · legal_authorities
### Statutory Notes
Section 137, act Aug. 5, 1937, ch. 565, § 1, 50 Stat. 559, provided for establishment of National Cancer Institute. See [section 281 of this title](https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title42-section281&num=0&edition=prelim).
Section 137a, act Aug. 5, 1937, ch. 565, § 2, 50 Stat. 559, provided for powers and duties of Surgeon General. See [section 282 of this title](https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title42-section282&num=0&edition=prelim).
Section 137b, act Aug. 5, 1937, ch. 565, § 3, 50 Stat. 560, provided for establishment of National Advisory Cancer Council. See [section 218 of this title](https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title42-section218&num=0&edition=prelim).
Section 137c, act Aug. 5, 1937, ch. 565, § 4, 50 Stat. 560, provided for powers and functions of Council. See [section 284 of this title](https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title42-section284&num=0&edition=prelim).
Section 137d, act Aug. 5, 1937, ch. 565, § 5, 50 Stat. 561, provided for administration of powers by Surgeon General. See [section 283 of this title](https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title42-section283&num=0&edition=prelim).
Section 137e, act Aug. 5, 1937, ch. 565, § 6, 50 Stat. 561, provided for acceptance of gifts. See [section 283 of this title](https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title42-section283&num=0&edition=prelim).
Section 137f, act Aug. 5, 1937, ch. 565, § 7, 50 Stat. 561, provided for appropriations. See [section 285 of this title](https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title42-section285&num=0&edition=prelim).
Section 137g, act Aug. 5, 1937, ch. 565, § 8, 50 Stat. 562, related t
Source: Supplied U.S. Code snapshot — release unconfirmed · 42 U.S.C. § 137 to 137g
Stored review status: release_metadata_unconfirmed. Incoming connection: Explicit cross-reference supplied in source Markdown; currentness and applicability require review.
Federal law — U.S. Code and appendices · legal_authorities
**(a) Appointment** The National Institutes of Health shall be headed by the Director of NIH who shall be appointed by the President by and with the advice and consent of the Senate. The Director of NIH shall perform functions as provided under subsection (b) and as the Secretary may otherwise prescribe.
**(b) Duties and authority** In carrying out the purposes of [section 241 of this title](https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title42-section241&num=0&edition=prelim), the Secretary, acting through the Director of NIH—
(1) shall carry out this subchapter, including being responsible for the overall direction of the National Institutes of Health and for the establishment and implementation of general policies respecting the management and operation of programs and activities within the National Institutes of Health;
(2) shall coordinate and oversee the operation of the national research institutes, national centers, and administrative entities within the National Institutes of Health;
(3) shall, in consultation with the heads of the national research institutes and national centers, be responsible for program coordination across the national research institutes and national centers, including conducting priority-setting reviews, to ensure that the research portfolio of the National Institutes of Health is balanced and free of unnecessary duplication, and takes advantage of collaborative, cross-cutting research;
(4) shall assemble accurate data to be used to assess research priorities, including—
(A) information to better evaluate scientific opportunity, public health burdens, and progress in reducing health disparities; and
(B) data on study populations of clinical research, funded by or conducted at each national research institute and
Source: Supplied U.S. Code snapshot — release unconfirmed · 42 U.S.C. § 282
Stored review status: release_metadata_unconfirmed. Incoming connection: Explicit cross-reference supplied in source Markdown; currentness and applicability require review.
Federal law — U.S. Code and appendices · legal_authorities
**(a) In general**
(1) **This subchapter** — For purposes of carrying out this subchapter, there are authorized to be appropriated—
(A) $30,331,309,000 for fiscal year 2007;
(B) $32,831,309,000 for fiscal year 2008;
(C) such sums as may be necessary for fiscal year 2009;
(D) $34,851,000,000 for fiscal year 2018;
(E) $35,585,871,000 for fiscal year 2019; and
(F) $36,472,442,775 for fiscal year 2020.
(2) **Funding for pediatric research initiative** — For the purpose of carrying out [section 282(b)(7)(B)(ii) of this title](https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title42-section282/b/7/B/ii&num=0&edition=prelim), there is authorized to be appropriated to the Division of Program Coordination, Planning, and Strategic Initiatives, out of the Pediatric Research Initiative Fund described in [section 9008 of title 26](https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title26-section9008&num=0&edition=prelim), and in addition to amounts otherwise made available under paragraph (1) of this subsection, $12,600,000 for each of fiscal years 2024 through 2028.
**(b) Office of the Director** Of the amount authorized to be appropriated under subsection (a) for a fiscal year, there are authorized to be appropriated for programs and activities under this subchapter carried out through the Office of the Director of NIH such sums as may be necessary for each of the fiscal years 2007 through 2009.
**(c) Trans-NIH research**
(1) **Common Fund**
(A) *Account* — For the purpose of allocations under [section 282(b)(7)(B)(i) of this title](https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title42-section282/b/7/B/i&num=0&edition=prelim) (relating to research identified by the Division of Program Coordination, Planning, and Strat
Source: Supplied U.S. Code snapshot — release unconfirmed · 42 U.S.C. § 282a
Stored review status: release_metadata_unconfirmed. Incoming connection: Explicit cross-reference supplied in source Markdown; currentness and applicability require review.
Federal law — U.S. Code and appendices · legal_authorities
**(a) Preparation** The Director of NIH, after consultation with the committee established under subsection (e), shall prepare a plan—
(1) for the National Institutes of Health to conduct or support research into—
(A) methods of biomedical research and experimentation that do not require the use of animals;
(B) methods of such research and experimentation that reduce the number of animals used in such research;
(C) methods of such research and experimentation that produce less pain and distress in such animals; and
(D) methods of such research and experimentation that involve the use of marine life (other than marine mammals);
(2) for establishing the validity and reliability of the methods described in paragraph (1);
(3) for encouraging the acceptance by the scientific community of such methods that have been found to be valid and reliable; and
(4) for training scientists in the use of such methods that have been found to be valid and reliable.
**(b) Submission to Congressional committees** Not later than October 1, 1993, the Director of NIH shall submit to the Committee on Energy and Commerce of the House of Representatives, and to the Committee on Labor and Human Resources of the Senate, the plan required in subsection (a) and shall begin implementation of the plan.
**(c) Periodic review and revision** The Director of NIH shall periodically review, and as appropriate, make revisions in the plan required under subsection (a). A description of any revision made in the plan shall be included in the first biennial report under [section 283 of this title](https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title42-section283&num=0&edition=prelim) that is submitted after the revision is made.
**(d) Dissemination of information** The Director of
Source: Supplied U.S. Code snapshot — release unconfirmed · 42 U.S.C. § 283e
Stored review status: release_metadata_unconfirmed. Incoming connection: Explicit cross-reference supplied in source Markdown; currentness and applicability require review.
Federal law — U.S. Code and appendices · legal_authorities
**(a) In general** Pursuant to the authorities and processes established under [section 3719 of title 15](https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title15-section3719&num=0&edition=prelim), the Director of the National Institutes of Health shall support prize competitions for one or both of the following goals:
(1) Identifying and funding areas of biomedical science that could realize significant advancements through a prize competition.
(2) Improving health outcomes, particularly with respect to human diseases and conditions—
(A) for which public and private investment in research is disproportionately small relative to Federal Government expenditures on prevention and treatment activities with respect to such diseases and conditions, such that Federal expenditures on health programs would be reduced;
(B) that are serious and represent a significant disease burden in the United States; or
(C) for which there is potential for significant return on investment to the United States.
**(b) Tracking; reporting** The Director of the National Institutes of Health shall—
(1) collect information on—
(A) the effect of innovations funded through the prize competitions under this section in advancing biomedical science or improving health outcomes pursuant to subsection (a); and
(B) the effect of the innovations on Federal expenditures; and
(2) include the information collected under paragraph (1) in the triennial report under [section 283 of this title](https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title42-section283&num=0&edition=prelim) (as amended by section 2032).
Source: Supplied U.S. Code snapshot — release unconfirmed · 42 U.S.C. § 283q
Stored review status: release_metadata_unconfirmed. Incoming connection: Explicit cross-reference supplied in source Markdown; currentness and applicability require review.
Federal law — U.S. Code and appendices · legal_authorities
**(a) Appointment**
(1) **In general** — The Director of the National Cancer Institute shall be appointed by the President, and the Directors of the other national research institutes and national centers shall be appointed by the Secretary, acting through the Director of National Institutes of Health. Each Director of a national research institute or national center shall report directly to the Director of National Institutes of Health.
(2) **Appointment**
(A) *Term* — A Director of a national research institute or national center who is appointed by the Secretary, acting through the Director of National Institutes of Health, shall be appointed for 5 years.
(B) *Reappointment* — At the end of the term of a Director of a national research institute or national center, the Director may be reappointed in accordance with standards applicable to the relevant appointment mechanism. There shall be no limit on the number of terms that a Director may serve.
(C) *Vacancies* — If the office of a Director of a national research institute or national center becomes vacant before the end of such Director’s term, the Director appointed to fill the vacancy shall be appointed for a 5-year term starting on the date of such appointment.
(D) *Current directors* — Each Director of a national research institute or national center who is serving on December 13, 2016, shall be deemed to be appointed for a 5-year term under this subsection beginning on such date.
(E) *Rule of construction* — Nothing in this subsection shall be construed to limit the authority of the Secretary or the Director of National Institutes of Health to terminate the appointment of a director referred to in subparagraph (A) before the expiration of such director’s 5-year term.
(F) *Nature of appointm
Source: Supplied U.S. Code snapshot — release unconfirmed · 42 U.S.C. § 284
Stored review status: release_metadata_unconfirmed. Incoming connection: Explicit cross-reference supplied in source Markdown; currentness and applicability require review.
Federal law — U.S. Code and appendices · legal_authorities
**(a) In general** The Secretary of Health and Human Services (referred to in this section as “the Secretary”) shall continue to conduct or support epidemiological, basic, translational, and clinical research related to vector-borne diseases, including tick-borne diseases.
**(b) Reports** The Secretary shall ensure that each triennial report under [section 283 of this title](https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title42-section283&num=0&edition=prelim) (as amended by section 2032) includes information on actions undertaken by the National Institutes of Health to carry out subsection (a) with respect to tick-borne diseases.
**(c) Tick-Borne Diseases Working Group**
(1) **Establishment** — The Secretary shall establish a working group, to be known as the Tick-Borne Disease Working Group (referred to in this section as the “Working Group”), comprised of representatives of appropriate Federal agencies and other non-Federal entities, to provide expertise and to review all efforts within the Department of Health and Human Services related to all tick-borne diseases, to help ensure interagency coordination and minimize overlap, and to examine research priorities.
(2) **Responsibilities** — The working group shall—
(A) not later than 2 years after December 13, 2016, develop or update a summary of—
(i) ongoing tick-borne disease research, including research related to causes, prevention, treatment, surveillance, diagnosis, diagnostics, duration of illness, and intervention for individuals with tick-borne diseases;
(ii) advances made pursuant to such research;
(iii) Federal activities related to tick-borne diseases, including—
(I) epidemiological activities related to tick-borne diseases; and
(II) basic, clinical, and tra
Source: Supplied U.S. Code snapshot — release unconfirmed · 42 U.S.C. § 284s
Stored review status: release_metadata_unconfirmed. Incoming connection: Explicit cross-reference supplied in source Markdown; currentness and applicability require review.
Federal law — U.S. Code and appendices · legal_authorities
**(a) Development of scientific framework**
(1) **In general** — For each recalcitrant cancer identified under subsection (b), the Director of the Institute shall develop (in accordance with subsection (c)) a scientific framework for the conduct or support of research on such cancer.
(2) **Contents** — The scientific framework with respect to a recalcitrant cancer shall include the following:
(A) *Current status*
(i) *Review of literature* — A summary of findings from the current literature in the areas of—
(I) the prevention, diagnosis, and treatment of such cancer;
(II) the fundamental biologic processes that regulate such cancer (including similarities and differences of such processes from the biological processes that regulate other cancers); and
(III) the epidemiology of such cancer.
(ii) *Scientific advances* — The identification of relevant emerging scientific areas and promising scientific advances in basic, translational, and clinical science relating to the areas described in subclauses (I) and (II) of clause (i).
(iii) *Researchers* — A description of the availability of qualified individuals to conduct scientific research in the areas described in clause (i).
(iv) *Coordinated research initiatives* — The identification of the types of initiatives and partnerships for the coordination of intramural and extramural research of the Institute in the areas described in clause (i) with research of the relevant national research institutes, Federal agencies, and non-Federal public and private entities in such areas.
(v) *Research resources* — The identification of public and private resources, such as patient registries and tissue banks, that are available to facilitate research relating to each of the areas descri
Source: Supplied U.S. Code snapshot — release unconfirmed · 42 U.S.C. § 285a–13
Stored review status: release_metadata_unconfirmed. Incoming connection: Explicit cross-reference supplied in source Markdown; currentness and applicability require review.